Cella G, Colby S I, Taylor A D, McCracken L, Parisi A F, Sasahara A A
Thromb Res. 1983 Mar 1;29(5):499-509. doi: 10.1016/0049-3848(83)90345-6.
The recent introduction of the determinations of platelet factor 4 (PF4) and beta-thromboglobulin (beta TG) by radioimmunoassay provided a new tool to obtain knowledge of in vivo platelet activation. We evaluated the plasma level of PF4 and beta TG in 14 normal subjects (mean PF4 7.7 ng/ml; beta TG 28.8 ng/ml), in 29 patients with chronic stable cardiovascular disorders (mean PF4 9.8 ng/ml; beta TG 32.6 ng/ml) and in 15 diabetics with vascular disease (mean PF4 14.5 ng/ml; beta TG 41.8 ng/ml). The great majority had normal values and no statistical differences were noted among the three groups (p greater than 0.05). Fifteen days of treatment with 150 mg daily of dipyridamole produced a significant reduction in the levels of both proteins (p less than 0.01), in contrast of the daily administration of 650 mg of aspirin, which failed to produce any significant change (p greater than 0.5). The patients and the normal subjects were also administered 3,000 USP units intravenously of porcine heparin. The values of the heparin released-platelet factor 4 (HR-PF4), evaluated 5 minutes after the injection, showed a good correlation between platelet concentration and HR-PF4 levels (z = 2.37, p less than 0.02) in the patients. The determination of standard residual following linear regression analysis of HR-PF4 indicated the presence of two distinct patient populations. One group, including the vast majority of patients, did not differ from the control (patients mean HR-PF4 111.1 ng/ml; controls: mean HF-PF4 136 ng/ml). The other group, with severe cardiovascular disease, but with normal levels of PF4 and beta TG in almost all patients and similar platelet concentrations, showed a significantly higher HR-PF4 (219 ng/ml). Neither aspirin nor dipyridamole had any effect on the level of HR-PF4. This HR-PF4 could represent a possible marker of the interaction of platelets with a seriously damaged atherosclerotic vessel wall.
最近通过放射免疫测定法测定血小板第4因子（PF4）和β-血小板球蛋白（βTG），为了解体内血小板活化情况提供了一种新工具。我们评估了14名正常受试者（PF4平均7.7 ng/ml；βTG 28.8 ng/ml）、29名慢性稳定心血管疾病患者（PF4平均9.8 ng/ml；βTG 32.6 ng/ml）和15名患有血管疾病的糖尿病患者（PF4平均14.5 ng/ml；βTG 41.8 ng/ml）的血浆PF4和βTG水平。绝大多数人的数值正常，三组之间未发现统计学差异（p大于0.05）。每天服用150 mg双嘧达莫治疗15天，两种蛋白质的水平均显著降低（p小于0.01），相比之下，每天服用650 mg阿司匹林则未产生任何显著变化（p大于0.5）。还对患者和正常受试者静脉注射3000 USP单位的猪肝素。注射后5分钟评估的肝素释放血小板第4因子（HR-PF4）值显示，患者的血小板浓度与HR-PF4水平之间存在良好的相关性（z = 2.37，p小于0.02）。对HR-PF4进行线性回归分析后确定的标准残差表明存在两个不同的患者群体。一组包括绝大多数患者，与对照组无差异（患者平均HR-PF4 111.1 ng/ml；对照组：平均HF-PF4 136 ng/ml）。另一组患有严重心血管疾病，但几乎所有患者的PF4和βTG水平正常且血小板浓度相似，其HR-PF4显著更高（219 ng/ml）。阿司匹林和双嘧达莫对HR-PF4水平均无任何影响。这种HR-PF4可能代表血小板与严重受损的动脉粥样硬化血管壁相互作用的一个可能标志物。
Zotero 插件